Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients
Latest Information Update: 17 Nov 2023
At a glance
- Drugs Paclitaxel (Primary) ; Varlitinib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms K-MASTER-13
Most Recent Events
- 08 Nov 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 27 May 2022 Status changed from recruiting to active, no longer recruiting.